Clinical Trial Search

Primary: Progression-free Survival (PFS) — 23.2; 11.5 months — p==0.012

Primary: Comparison of Participant Clinical Status Between Treatment Arms — 28; 40; 112; 129 participants — p=0.008

Primary: Mean Total Scholastic Skills Score (a Sum of Three Scales: Reading, Spelling, and Counting). — 61.39; 60.46; 79.94; 74.56 score on a scale — p=0.0113

Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 76.0; 78.6 percentage of participants

Primary: Change From Baseline to Day 43 in Myasthenia Gravis-Activities of Daily Living (MG-ADL) Score — -0.784; -3.370; -3.403 units on a scale — p=<0.001

Primary: Radiographic Progression-free Survival (rPFS) by IRR in Participants With a BRCA Alteration — 11.2; 6.4 months — p=<0.001

Primary: Effect of Vitamin D Supplementation on Albuminuria in CKD Patients as Assessed by Urine Albumin/Creatinine Measures. — 1126.68; 1061.39 mg/gram creatinine

Primary: Change in ASD Symptoms Social Responsiveness Scale 2 (SRS-2) Scale From Baseline to Week 8 — -39.5; -29 scores on a scale

Primary: Numerical Rating Scale (NRS) Pain Score at Baseline — 8.3; 8.1 score on a scale

Primary: Change From Baseline in Abnormal Involuntary Movement Scale (AIMS) Total Score (Central Assessment) at Week 6 — -0.1; -2.3; -3.7 units on a scale — p=<0.001

Primary: Percent of Subjects' Study Eyes With Pupil Diameter Returning to Baseline — 46; 6 Participants

Primary: Intraoperative Systemic Oxidative Damage — 69; 83 pg/ml

Primary: Percentage of Participants Obtaining Successful Treatment — 4; 3; 2 Participants

Primary: Change in Testosterone (T) Levels — 219.5; 202.3; 543; 696.5 ng/dL

Primary: Number of Occurrences of Protocol-Defined Respiratory Illness Caused by Vaccine-Matched Influenza Strains — 110; 169 Number of cases